ELMWOOD PARK, N.J.--(BUSINESS WIRE)--Based on its recent analysis of the clinical diagnostics market, Frost & Sullivan recognized GenPath Diagnostics, a business unit of BioReference Laboratories, Inc ...

Cambridge-based GenPath Pharmaceuticals Inc., a drug discovery and development company focused on the treatment of cancer and other diseases, announced today that it has entered into a multi-year ...

Kenneth Weg, former vice chairman of Bristol-Myers Squibb, first heard the details about a technology to prioritize the best drug targets about a year ago. Raju Kucherlapati, a fellow member of the ...

GenPath Pharmaceuticals has signed a collaborative agreement with drugmajor Merck & Co in the field of oncology, under which the former will utilize its proprietary cancer models to identify essential ...

GenPath's growth stems from its ability to provide proprietary and highly differentiated tests in addition to comprehensive cancer laboratory tests in-house. June 26, 2012 Based on its recent analysis ...

- GenPath's growth stems from its ability to provide proprietary and highly differentiated tests in addition to comprehensive cancer laboratory tests in-house. GenPath provides complete cancer ...

Bio-Reference Laboratories, Inc. has announced that K-ras mutation testing for patients with metastatic colorectal (mCRC) or non-small-cell lung (NSCLC) cancers will now be available through the ...

Cancer and genetics medicine developer GenPath has raised $15.5 millionthrough a Series A financing. Leading the round was MPM Capital, joined by Venrock Associates, Prospect Venture Partners, Geylock ...